Pitavastatin Pre-Treatment Study in Patient With Elective PCI for Stable Angina Pectoris (PIPA)

• Status: Withdrawn
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients who is scheduled elective PCI are randomized to pitavastatin 4mg daily or without pitavastatin for 5 -7days before the procedure. Creatine kinase-MB, troponin I, and myoglobin levels are measured at baseline and at 8 and 24 hours after the procedure(1st evaluation). After PCI, pitavastatin will be administered for additional 4 weeks(2nd evaluation).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: JW Pharmaceutical
• Treatments: Pitavastatin

Criteria

Inclusion Criteria:

• Patients with LDL ≥ 100mg/dL

• Patients who are scheduled an elective PCI for stable angina

Exclusion Criteria:

• Acute myocardial infarction (<3 months)

• Unstable angina

• Previous treatment with statins (<6 months)

• Increase in CK-MB above upper normal limit

• Increase in liver enzymes (AST/ALT) above 2 times of upper normal limit

• Increase in serum creatinine above 2 times of upper normal limit

• Left ventricular ejection fraction <30%

• Previous treatment with glycoprotein Ⅱb/Ⅲa receptor inhibitor (<4 weeks)